Pharmacoeconomic aspects of the treatment of pituitary gland tumours

Jerzy Sowiński; Nadia Sawicka; Katarzyna Piątek; Ariadna Zybek; Marek Ruchała

doi:10.5114/wo.2013.34616

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2013
vol. 17

Send email

Copy url:

abstract:

Review paper

Pharmacoeconomic aspects of the treatment of pituitary gland tumours

Jerzy Sowiński

,

Nadia Sawicka

,

Katarzyna Piątek

,

Ariadna Zybek

,

Marek Ruchała

Wspolczesna Onkol 2013; 17 (2): 137–143

DOI: https://doi.org/10.5114/wo.2013.34616

Online publish date: 2013/04/29

View full text Get citation

PlumX metrics:

Nowadays physicians are under economic pressure; therefore therapeutic decisions based on safety, efficacy, and the effectiveness of the medication also require economic analysis. The aim of this review is to discuss data concerning the cost-effectiveness of drug therapy in patients with hormonally active pituitary adenomas, namely growth hormone, adrenocorticotropic hormone, thyroid-stimulating hormone-secreting pituitary adenomas, prolactinoma and pituitary incidentaloma.

In acromegalic patients using lanreotide is cheaper for health care payers and more convenient for physicians and patients because of the opportunity for self/partner injections, lower clogging risk and possibility of longer intervals between injections, while the efficacy is comparable with octreotide. Patients with prolactinomas should be treated with novel dopamine agonists, such as cabergoline or quinagolide, however, bromocriptine still remains a cheaper and almost as effective alternative.

There are no easy methods or algorithms, but in general, extracting the maximum value from the investment in treatment is essential.

keywords:

Pharmacoeconomic aspects of the treatment of pituitary gland tumours

Jerzy Sowiński , Nadia Sawicka , Katarzyna Piątek , Ariadna Zybek , Marek Ruchała

pharmacoeconomics, lanreotide, octreo­tide, acromegaly, prolactinoma, ACTH-secreting pituitary adenoma

Jerzy Sowiński

,

Nadia Sawicka

,

Katarzyna Piątek

,

Ariadna Zybek

,

Marek Ruchała

pharmacoeconomics, lanreotide, octreotide, acromegaly, prolactinoma, ACTH-secreting pituitary adenoma